[go: up one dir, main page]

WO2000006185A3 - Procedes d'utilisation d'un analogue de somatostatine - Google Patents

Procedes d'utilisation d'un analogue de somatostatine Download PDF

Info

Publication number
WO2000006185A3
WO2000006185A3 PCT/US1999/017294 US9917294W WO0006185A3 WO 2000006185 A3 WO2000006185 A3 WO 2000006185A3 US 9917294 W US9917294 W US 9917294W WO 0006185 A3 WO0006185 A3 WO 0006185A3
Authority
WO
WIPO (PCT)
Prior art keywords
conditions
diseases
cys
lanreotide
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/017294
Other languages
English (en)
Other versions
WO2000006185A2 (fr
Inventor
Jacques-Pierre Moreau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Bioscience Inc
Original Assignee
Ipsen Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002335654A priority Critical patent/CA2335654A1/fr
Priority to AU52447/99A priority patent/AU770193B2/en
Priority to BR9912609-5A priority patent/BR9912609A/pt
Priority to JP2000562039A priority patent/JP2002521456A/ja
Priority to MXPA01000969A priority patent/MXPA01000969A/es
Priority to PL99346361A priority patent/PL346361A1/xx
Priority to EP99937658A priority patent/EP1100532A2/fr
Priority to HU0102839A priority patent/HUP0102839A3/hu
Priority to KR1020017001277A priority patent/KR20010071071A/ko
Application filed by Ipsen Bioscience Inc filed Critical Ipsen Bioscience Inc
Priority to NZ509348A priority patent/NZ509348A/xx
Priority to IL14083799A priority patent/IL140837A0/xx
Publication of WO2000006185A2 publication Critical patent/WO2000006185A2/fr
Publication of WO2000006185A3 publication Critical patent/WO2000006185A3/fr
Priority to NO20010481A priority patent/NO324123B1/no
Anticipated expiration legal-status Critical
Priority to AU2004201783A priority patent/AU2004201783A1/en
Priority to IL181349A priority patent/IL181349A0/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un procédé de traitement d'une ou plusieurs des maladies et/ou conditions suivantes. Ce procédé consiste à administrer à un patient le composé H-β-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2. Les cystéines sont liées par une liaison disulfure ou un sel pharmaceutiquement acceptable de ces dernières, de préférence, le sec acétate du composé, pour traiter certaines maladies et/ou états tels que des conditions et/ou maladies gastroentérologiques, des maladies et/ou des états endocrinologiques, divers types de cancers et états associés à un cancer tel qu'une cachexie de cancer et dans le traitement de l'hypotension et des crises de panique.
PCT/US1999/017294 1998-07-30 1999-07-29 Procedes d'utilisation d'un analogue de somatostatine Ceased WO2000006185A2 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
KR1020017001277A KR20010071071A (ko) 1998-07-30 1999-07-29 성장억제 호르몬 유사체의 사용방법
BR9912609-5A BR9912609A (pt) 1998-07-30 1999-07-29 Métodos de uso de um análogo de somatostatina
NZ509348A NZ509348A (en) 1998-07-30 1999-07-29 Use of a somatostatin analogue Lanreotide
MXPA01000969A MXPA01000969A (es) 1998-07-30 1999-07-29 Metodo de uso de un analogo de somatostatina.
PL99346361A PL346361A1 (en) 1998-07-30 1999-07-29 Methods of using a somatostatin analogue
EP99937658A EP1100532A2 (fr) 1998-07-30 1999-07-29 Procedes d'utilisation d'un analogue de somatostatine
HU0102839A HUP0102839A3 (en) 1998-07-30 1999-07-29 Methods of using lanreotide, a somatostatin analogue and pharmaceutical compositions comprising thereof
CA002335654A CA2335654A1 (fr) 1998-07-30 1999-07-29 Procedes d'utilisation d'un analogue de somatostatine
JP2000562039A JP2002521456A (ja) 1998-07-30 1999-07-29 ソマトスタチン類似体の使用法
AU52447/99A AU770193B2 (en) 1998-07-30 1999-07-29 Methods of using a somatostatin analogue
IL14083799A IL140837A0 (en) 1998-07-30 1999-07-29 Method of using lanreotide, a somatostatin analogue
NO20010481A NO324123B1 (no) 1998-07-30 2001-01-29 Anvendelse av lanreotid, eller et farmasoytisk akseptabelt salt derav for fremstilling av et farmasoytisk preparat
AU2004201783A AU2004201783A1 (en) 1998-07-30 2004-04-29 Methods of using a somatostatin analogue
IL181349A IL181349A0 (en) 1998-07-30 2007-02-15 Method of using lanreotide, a somatostatin analogue for preparation of medicaments for treating diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12652598A 1998-07-30 1998-07-30
US9469398P 1998-07-30 1998-07-30
US60/094,693 1998-07-30
US09/126,525 1998-07-30

Publications (2)

Publication Number Publication Date
WO2000006185A2 WO2000006185A2 (fr) 2000-02-10
WO2000006185A3 true WO2000006185A3 (fr) 2000-08-03

Family

ID=26789150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017294 Ceased WO2000006185A2 (fr) 1998-07-30 1999-07-29 Procedes d'utilisation d'un analogue de somatostatine

Country Status (16)

Country Link
EP (1) EP1100532A2 (fr)
JP (1) JP2002521456A (fr)
KR (1) KR20010071071A (fr)
CN (1) CN1334742A (fr)
AR (1) AR023633A1 (fr)
AU (2) AU770193B2 (fr)
BR (1) BR9912609A (fr)
CA (1) CA2335654A1 (fr)
CZ (1) CZ2001157A3 (fr)
HU (1) HUP0102839A3 (fr)
IL (2) IL140837A0 (fr)
MX (1) MXPA01000969A (fr)
NO (1) NO324123B1 (fr)
NZ (1) NZ509348A (fr)
PL (1) PL346361A1 (fr)
WO (1) WO2000006185A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1040837A3 (fr) * 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Médicaments pour le traitement des troubles liés à la néovascularisation de lachoroide
AU2001283957A1 (en) * 2000-07-27 2002-02-13 Novartis Ag Treatment of ocular disorders with somatostatin analogues
US6316414B1 (en) 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
DE60220157T2 (de) 2001-03-06 2008-01-17 Il Consorzio Ferrara Richerche Verfahren zur modulierung der proliferation von medullären schilddrüsen-karzinomzellen
GB0109461D0 (en) * 2001-04-18 2001-06-06 Univ London New Gene
US20110034381A1 (en) 2002-01-22 2011-02-10 David Kleinberg Methods for Therapeutic Treatment of Benign Prostatic Hypertrophy (BPH)
BRPI0915888E2 (pt) 2008-06-12 2020-09-01 Syntaxin Ltd polipetídeo, seu método de ativação, sequência de ácido nucléico codificando o mesmo e seu uso
CN102083451A (zh) 2008-06-12 2011-06-01 赛恩泰新公司 癌症的抑制
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN101935252B (zh) * 2010-07-29 2013-01-30 广东省农业科学院科技情报研究所 一种园林植物生长延缓剂及其制备方法
US9333234B2 (en) * 2012-04-12 2016-05-10 Novartis Ag Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
CN105168115A (zh) * 2015-09-02 2015-12-23 中国药科大学 生长抑素类似物多肽药物的口服给药途径
WO2017212390A1 (fr) * 2016-06-06 2017-12-14 Emcure Pharmaceuticals Ltd, Procédé de préparation d'acétate de lanréotide

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US5506339A (en) * 1989-12-08 1996-04-09 The Administrators Of The Tulane Educational Fund Octapeptide analogs of somatostatin having threonine at the sixth position
US5688530A (en) * 1989-07-07 1997-11-18 Novartis Ag Sustained release formulations of water soluble peptides
WO1998008529A1 (fr) * 1996-08-30 1998-03-05 Biomeasure Incorporated Procede d'inhibition de la fibrose a l'aide d'un agoniste de somatostatine
WO1998010786A2 (fr) * 1996-09-12 1998-03-19 Yarom Cohen Composition pharmaceutique pour le traitement du syndrome x de reaven
WO1998051332A1 (fr) * 1997-05-13 1998-11-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Somatostatine et agonistes de somatostatine pour traiter l'insensibilite a l'insuline et le syndrome x

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US5688530A (en) * 1989-07-07 1997-11-18 Novartis Ag Sustained release formulations of water soluble peptides
US5506339A (en) * 1989-12-08 1996-04-09 The Administrators Of The Tulane Educational Fund Octapeptide analogs of somatostatin having threonine at the sixth position
WO1998008529A1 (fr) * 1996-08-30 1998-03-05 Biomeasure Incorporated Procede d'inhibition de la fibrose a l'aide d'un agoniste de somatostatine
WO1998010786A2 (fr) * 1996-09-12 1998-03-19 Yarom Cohen Composition pharmaceutique pour le traitement du syndrome x de reaven
WO1998051332A1 (fr) * 1997-05-13 1998-11-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Somatostatine et agonistes de somatostatine pour traiter l'insensibilite a l'insuline et le syndrome x

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
ANTHONY L B ET AL: "Case report: lanreotide in the management of hypercalcemia of malignancy.", AMERICAN JOURNAL OF THE MEDICAL SCIENCES, vol. 309, no. 6, June 1995 (1995-06-01), pages 312 - 314, XP000867465 *
BARTLETT D L ET AL: "Reversal of tumor-associated hyperglucagonemia as treatment for cancer cachexia.", SURGERY (ST LOUIS), vol. 118, no. 1, July 1995 (1995-07-01), pages 87 - 97, XP000907234 *
CHANSON P: "Traitements médicamenteux des adénomes hypophysaires.", REVUE DU PRATICIEN, vol. 46, 15 June 1996 (1996-06-15), pages 1509 - 1513, XP000907252 *
HASLER W ET AL: "ROLE OF THE PYLORUS IN THE PREVENTION OF DUODENO-GASTRIC REFLUX EFFECTS OF THE SOMATOSTATIN ANALOG.", GASTROENTEROLOGY, vol. 100, no. 5, 19 May 1991 (1991-05-19) - 22 May 1991 (1991-05-22), pages A448, XP000866191 *
HOELDTKE R D ET AL: "Treatment of orthostatic hypotension with midodrine and octreotide.", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 83, no. 2, February 1998 (1998-02-01), pages 339 - 343, XP000907222 *
JAFFRAIN-REA ML ET AL: "Visual improvement during octreotide therapy in a case of episellar meningioma.", CLINICAL NEUROLOGY AND NEUROSURGERY, vol. 100, no. 1, March 1998 (1998-03-01), pages 40 - 43, XP000907228 *
KANG S & MISHKIN F S: "Visualization of Paget's disease during somatostatin receptor scintigraphy.", CLINICAL NUCLEAR MEDICINE, vol. 24, no. 11, November 1999 (1999-11-01), pages 900 - 902, XP000907230 *
KHOO D ET AL: "Palliation of malignant intestinal obstruction using octreotide", EUROPEAN JOURNAL OF CANCER, vol. 30A, no. 1, 1994, pages 28 - 30, XP000866064 *
KIRK J M W ET AL: "Somatostatin analogue in short term management of hyperinsulinism", ARCHIVES OF DISEASE IN CHILDHOOD, vol. 63, no. 12, 1988, pages 1493-1494, XP002053035 *
LAMRANI A ET AL: "Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans.", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 43, no. 1, January 1997 (1997-01-01), pages 65 - 70, XP000870053 *
MOSDELL K W ET AL: "Emerging indications for octreotide therapy, Part 1.", AMERICAN JOURNAL OF HOSPITAL PHARMACY, vol. 51, no. 9, 1 May 1994 (1994-05-01), pages 1184 - 1192, XP000866264 *
MOTTET C ET AL: "Hemodynamic effects of the somatostatin analog lanreotide in humans: placebo-controlled, cross-over dose-ranging Echo-Doppler study.", HEPATOLOGY, vol. 27, no. 4, April 1998 (1998-04-01), pages 920 - 925, XP000870061 *
ONO, MASASHI ET AL: "Effects of octreotide acetate treatment for scleroderma bowel.", KAWASAKI MEDICAL JOURNAL, vol. 22, no. 4, 1996, pages 233 - 237, XP000866213 *
PAVLOVIC M. ET AL: "Regression of sclerodermatous skin lesions in a patient with carcinoid syndrome treated by octreotide.", ARCHIVES OF DERMATOLOGY, vol. 131, no. 10, October 1995 (1995-10-01), pages 1207-1209, XP000866063 *
RIEU M ET AL: "Paradoxical effect of somatostatin analogues on the ectopic secretion of corticotropin in two cases of small cell lung carcinoma.", HORMONE RESEARCH, vol. 39, no. 5-6, November 1993 (1993-11-01), pages 207 - 212, XP000907231 *
SOBHANI I ET AL: "Lanreotide inhibits human jejunal secretion induced by prostaglandin E1 in healthy volunteers.", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 41, no. 2, February 1996 (1996-02-01), pages 109 - 114, XP000870052 *
SRKALOVIC G ET AL: "EVALUATION OF RECEPTORS FOR SOMATOSTATIN IN VARIOUS TUMORS USING DIFFERENT ANALOGS", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 70, no. 3, March 1990 (1990-03-01), pages 661 - 669, XP000907224 *
WECKBECKER G ET AL: "SOMATOSTATIN ANALOGS FOR DIAGNOSIS AND TREATMENT OF CANCER", PHARMACOLOGY AND THERAPEUTICS, vol. 60, no. 2, 1994, pages 245 - 264, XP002072560 *
WOLTERING E A ET AL: "DETECTION OF OCCULT GASTRINOMAS WITH IODINE 125-LABELED LANREOTIDE AND INTRAOPERATIVE GAMMA-DETECTION", SURGERY, vol. 116, no. 6, December 1994 (1994-12-01), pages 1139 - 1147, XP000866097 *
ZEILKE A ET AL: "Octreotide: Effective treatment for hyperparathyroidism? A prospective, randomized, controlled clinical trial.", SURGERY (ST LOUIS), vol. 121, no. 6, June 1997 (1997-06-01), pages 606 - 610, XP000907227 *

Also Published As

Publication number Publication date
NO20010481D0 (no) 2001-01-29
CN1334742A (zh) 2002-02-06
BR9912609A (pt) 2001-05-02
JP2002521456A (ja) 2002-07-16
AU5244799A (en) 2000-02-21
CZ2001157A3 (cs) 2002-02-13
AR023633A1 (es) 2002-09-04
IL140837A0 (en) 2002-02-10
MXPA01000969A (es) 2003-04-07
HUP0102839A2 (hu) 2002-01-28
HUP0102839A3 (en) 2002-02-28
NO20010481L (no) 2001-03-21
NO324123B1 (no) 2007-08-27
AU2004201783A1 (en) 2004-05-27
EP1100532A2 (fr) 2001-05-23
AU770193B2 (en) 2004-02-12
PL346361A1 (en) 2002-02-11
NZ509348A (en) 2004-02-27
IL181349A0 (en) 2007-07-04
KR20010071071A (ko) 2001-07-28
WO2000006185A2 (fr) 2000-02-10
CA2335654A1 (fr) 2000-02-10

Similar Documents

Publication Publication Date Title
WO2000006185A3 (fr) Procedes d'utilisation d'un analogue de somatostatine
WO2003096990A3 (fr) Cages proteiques pour l'administration d'agents therapeutiques et d'imagerie medicale
CA2146973A1 (fr) Utilisations d'un fragment du recepteur du tgf-.beta. a des fins therapeutiques
CA2301057A1 (fr) Procede permettant d'administrer un taxane liposomal encapsule
WO2003079979A3 (fr) Procede de traitement d'insuffisance cardiaque globale
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
WO1999064059A3 (fr) Utilisation de la secretine pour le traitement de l'autisme et d'autres troubles du comportement, troubles neurologiques ou immunologiques
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
WO1999004772A3 (fr) Levobupivacine et son utilisation
WO2002060389A3 (fr) Procede permettant de traiter l'insuffisance cardiaque chronique et/ou des taux de cholesterol eleves par l'acide 3,5-diiodothyropropionique et procede de preparation de ce dernier
WO2001009138A3 (fr) Antagonistes du recepteur de chimiokine et procedes d'utilisation associes
EP1251126A3 (fr) Derives de benzenesulfonyle a substitution fluor pour le traitment d'inflammation
WO2005002526A3 (fr) Procedes et compositions pour le traitement d'infections virales
WO2003079991A3 (fr) Technique d'administration d'hormone de croissance par voie pulmonaire
WO2003034996A3 (fr) Utilisation de leptine pour traiter la lipoatrophie humaine et procede pour determiner une predisposition a ce traitement
WO2002094189A3 (fr) Compositions et procedes de traitement ou de prevention de convulsions ou de crises
WO2005027936A3 (fr) Traitement au moyen d'oligo-beta-(1,3)- glucanes et medicament utilises dans le cadre de ce traitement
WO2004020668A3 (fr) Methode de traitement du synovialome
WO2004073615A3 (fr) Composes de deazaflavine et leurs methodes d'utilisation
WO2004007676A3 (fr) Therapie combinee servant a traiter des tumeurs
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
WO2003045942A3 (fr) Antagonistes des recepteurs de la chimiokine et methodes d'utilisation de ces antagonistes
WO1999065475A3 (fr) Combinaison de phentolamine et apomorphine pour le traitement concernant les fonctions et les dysfonctionnements sexuels
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
WO2004030607A3 (fr) Therapie d'immunisation passive a base peptidique pour le traitement de l'atherosclerose

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99808953.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 140837

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2001-157

Country of ref document: CZ

Ref document number: 1999937658

Country of ref document: EP

Ref document number: 509348

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 52447/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2335654

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000969

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 562039

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/00793

Country of ref document: ZA

Ref document number: 200100793

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020017001277

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999937658

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09744846

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017001277

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2001-157

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1999937658

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017001277

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 52447/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 181349

Country of ref document: IL

WWR Wipo information: refused in national office

Ref document number: PV2001-157

Country of ref document: CZ